Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LIPE | Q05469 | 3/20 | 0.44 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.40 |
| ▸ | HPGD | P15428 | 1/20 | 0.40 |
| ▸ | GAA | P10253 | 1/20 | 0.39 |
| ▸ | CTSK | P43235 | 4/20 | 0.38 |
| ▸ | CTSL | P07711 | 1/20 | 0.38 |
| ▸ | CTSB | P07858 | 1/20 | 0.38 |
| ▸ | EPHX1 | P07099 | 2/20 | 0.38 |
| ▸ | HTT | P42858 | 1/20 | 0.38 |
| ▸ | CA1 | P00915 | 1/20 | 0.37 |
| ▸ | CA2 | P00918 | 1/20 | 0.37 |
| ▸ | BTK | Q06187 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7365934 | 1.00 | LIPE (0.44) | LIPEL3MBTL1HPGDGAACTSK | |
| SCHEMBL477283 | 0.98 | LIPE (0.42) | LIPEL3MBTL1HPGDGAACTSK | |
| SCHEMBL1576452 | 0.94 | CTSK (0.40) | LIPEL3MBTL1GAACTSKCTSL | |
| SCHEMBL27760998 | 0.85 | EPHX1 (0.38) | LIPEL3MBTL1HPGDGAACTSK | |
| SCHEMBL28702168 | 0.85 | USP2 (0.39) | LIPEL3MBTL1GAACTSKCTSL | |
| SCHEMBL28942305 | 0.85 | EPHX1 (0.41) | LIPEL3MBTL1GAACTSKCTSL | |
| SCHEMBL7151133 | 0.83 | GNAI3 (0.38) | LIPEL3MBTL1GAACTSKCTSL | |
| SCHEMBL1430236 | 0.83 | LIPE (0.36) | LIPEL3MBTL1GAACTSKCTSL | |
| SCHEMBL5651167 | 0.81 | LIPE (0.39) | LIPEL3MBTL1GAACTSKCTSL | |
| SCHEMBL7449407 | 0.81 | KDM4E (0.42) | LIPEL3MBTL1GAACTSLHTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 376 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-110078657-A | A kind of synthetic method of chirality 3- amino piperidine and its derivative | 湖州复华春生物医药科技有限公司 | 2019-08-02 | — | — | CN | claimed |
| CN-104016977-B | A kind of replacement thiadiazine diketone derivative and preparation method thereof and application | 山东大学 | 2016-06-22 | — | — | CN | claimed |
| US-12600732-B2 | Bifunctional compounds for degrading BTK via ubiquitin proteosome pathway | NURIX THERAPEUTICS, INC. (US) | 2026-04-14 | — | — | US | disclosed |
| US-12582722-B2 | Bifunctional compounds for degrading BTK via ubiquitin proteosome pathway | NURIX THERAPEUTICS, INC. (US) | 2026-03-24 | — | — | US | disclosed |
| EP-4570320-A2 | BIFUNCTIONAL COMPOUNDS FOR DEGRADING BTK VIA UBIQUITIN PROTEOSOME PATHWAY | Nurix Therapeutics, Inc. (US) | 2025-06-18 | — | — | EP | disclosed |
| CN-115916765-B | Pyridine or pyrimidine derivative and preparation method and application thereof | 浙江海正药业股份有限公司 | 2025-04-18 | — | — | CN | disclosed |
| EP-4069237-B1 | BIFUNCTIONAL COMPOUNDS FOR DEGRADING BTK VIA UBIQUITIN PROTEOSOME PATHWAY | NURIX THERAPEUTICS INC (US) | 2025-04-09 | — | — | EP | disclosed |
| WO-2024208187-A1 | AZAARYL COMPOUND AND USE THEREOF AS LSD1 INHIBITOR | 上海复星医药（集团）股份有限公司 | 2024-10-10 | — | — | WO | disclosed |
| CN-114763357-B | Indolopyrimidine tricyclic compound and preparation method and application thereof | 中国科学院上海药物研究所 | 2024-06-18 | — | — | CN | disclosed |
| CN-118076607-A | Novel PLK1 degradation inducing compounds | 厄普特拉株式会社 | 2024-05-24 | — | — | CN | disclosed |
| US-11912721-B2 | Fused pentacyclic imidazole derivatives | UCB Biopharma SRL (BE) | 2024-02-27 | — | — | US | disclosed |
| CN-1265656-A | O-substituted hydroxycumaranone derivatives as anttumor and antimetastatic agents | HOFFMANN LA ROCHE (CH) | 2000-09-06 | — | — | CN | disclosed |
| EP-0998285-A1 | ALPHA 1a ADRENERGIC RECEPTOR ANTAGONISTS | Merck & Co., Inc. (US) | 2000-05-10 | — | — | EP | disclosed |
| EP-0733051-B1 | BICYCLIC HETEROCYCLES AS NEUROKININ A ANTAGONISTS | ZENECA LTD (GB) | 1999-09-15 | — | — | EP | disclosed |
| EP-0667858-B1 | 4-CARBOXOAMIDO PIPERIDINE DERIVATIVES, INTERMEDIATES AND USE AS NEUROKININ ANTAGONISTS | ZENECA LTD (GB) | 1999-08-25 | — | — | EP | disclosed |
| EP-0897913-A1 | 4-carboxamido piperidine derivatives and their use as neurokinine antagonists | ZENECA LIMITED (GB) | 1999-02-24 | — | — | EP | disclosed |
| WO-1998057641-A1 | ALPHA 1a ADRENERGIC RECEPTOR ANTAGONISTS | MERCK & CO., INC. (US) | 1998-12-23 | — | — | WO | disclosed |
| CN-1049164-A | Suppress Aminooligohydroxy derivatives of feritin and preparation method thereof | HOECHST AG (DE) | 1991-02-13 | — | — | CN | disclosed |
| US-4382892-A | Benzoxazine derivatives | DAIICHI SEIYAKU CO., LTD. (JP) | 1983-05-10 | — | — | US | disclosed |
| EP-0047005-A1 | Benzoxazine derivatives | DAIICHI SEIYAKU CO., LTD. (JP) | 1982-03-10 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12582722-B2 | Bifunctional compounds for degrading BTK via ubiquitin proteosome pathway | PSMB2, PSME3, PSMB3 | LIPE 2860/4885L3MBTL1 1179/4885HPGD 4554/4885 |
| US-11912721-B2 | Fused pentacyclic imidazole derivatives | TNF, NFKBIA, TNFRSF1A | LIPE 4425/4885L3MBTL1 3573/4885HPGD 90/4885 |
| US-12600732-B2 | Bifunctional compounds for degrading BTK via ubiquitin proteosome pathway | BTK, BCL9, BCL9L | LIPE 2910/4885L3MBTL1 1491/4885HPGD 4696/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.